METHYLPHENIDATE | A210924 | ACTAVIS ELIZABETH LLC AN INDIRECT WHOLLY OWNED SUB OF TEVA PHARMACEUTICALS USA INC
| Case | Court | Filed | Status | Judge |
|---|---|---|---|---|
Neos Therapeutics, Inc. et al v. Teva Pharmaceuticals USA, Inc. 3 patentsANDA 210924methylphenidate | D. Del. | 2017-12-13 | Terminated 2019-01-02 | — |
Source: PACER. NOS 835 (Patent - Abbreviated New Drug Application).
No patent or exclusivity listings for this strength.
Actavis Elizabeth changed methylphenidate (NDA 210924, Supplement 003) status from discontinued to prescription product.
Old: DISCN
New: RX
Actavis Elizabeth's methylphenidate product (NDA 210924, strength 001) received an AB therapeutic equivalence rating, permitting generic substitution.
New: AB
Actavis Elizabeth's methylphenidate NDA 210924 received a therapeutic equivalence code of AB, indicating bioequivalence to the reference product.
New: AB
Actavis Elizabeth's methylphenidate NDA 210924 received a therapeutic equivalence rating change to AB, indicating bioequivalent generic substitutability.
New: AB
Actavis Elizabeth's methylphenidate product (NDA 210924) status changed from discontinued to active prescription drug.
Old: DISCN
New: RX
Actavis Elizabeth's methylphenidate product (NDA 210924) status changed from discontinued to active prescription drug.
Old: DISCN
New: RX